Citius Pharmaceuticals is trading 6.1% higher at $0.51 in pre-market on October 7, 2026; no clear company-specific catalyst was identified.
- Shares fell 7.56% to $0.48 at the October 6 close.
- Recent coverage focused on previously reported fiscal third-quarter results and a registered direct offering reported as closed; neither appears to be a new October 7 announcement.
- Broader market indicators are mixed, so the rise cannot confidently be attributed to market sentiment.